Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Seeks Independence For API Unit Despite Stormy Market

IPO Plans Shelved In Favor Of Spin-Off

Executive Summary

The French drugmaker is pushing ahead with a listing of its Euroapi business on the Euronext in the next couple of months, in spite of the turbulence that the Russian invasion of Ukraine has brought to stock markets.

You may also be interested in...



Sanofi Takes Manufacturing Up A Gear With McLaren Pact

By tapping into the data analytics and expertise used to choreograph pitstops in Formula One, the French drugmaker is hoping to “maximize performance and operational excellence,” according to CEO Paul Hudson.

Sanofi Unruffled By JAK Threat To Dupixent

CEO Paul Hudson tells Scrip that in an atopic dermatitis market that has a standard of care like Dupixent, "it's hard to justify the role of a JAK unless somebody has, frankly, failed everything else."

Sanofi's Rilzabrutinib Fails At First Hurdle In Pemphigus Study

Analysts who felt Sanofi paid way over the odds when splashing out $3.7bn to buy Principia last year will be feeling justified in that stance after one of the oral BTK inhibitors acquired, rilzabrutinib, proved to be no more effective than placebo in a Phase III trial.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel